Vivacitas Oncology Presents for the Second Year in a row at the 2022 SAPA Conference
Somerset, NJ, USA, October 1, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, presents on October 1st, 2022 at the 2022 Sino-American Pharmaceutical Professional Association (SAPA) Conference. The SAPA Annual Conference is a tremendous platform for participants to share knowledge and viewpoints on important issues and […]
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company’s Neuro-Oncology Medical Advisory Board
Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director for Dana-Farber Cancer Institute, Center for Neuro-Oncology as a new member of its top-tier Neuro-Oncology […]
Dr. Gerard Blobe, MD, PhD Joins Vivacitas Oncology’s Solid Tumor Medical Advisory Board
Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Gerard Blobe, MD, PhD has joined its Medical Advisory Board. Tina Runk, EVP of Clinical Operations and Director of the company, commented on Dr. Blobe’s addition to Vivacitas’ team: “We very much appreciate […]
Vivacitas Oncology to Present at the 2022 BIO CEO & Investor Conference
Walnut Creek, CA, USA, February 14th, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, will present at the upcoming 2022 BIO CEO & Investor Conference, which will be held in New York City on February 14-17, 2022. Hosted by the Biotechnology Innovation Organization (BIO) for over 20 years, the annual event is focused […]
Dr. Volker W. Stieber, MD, Joins Vivacitas’ Neuro-Oncology Advisory Board
Walnut Creek, CA, USA, February 7, 2022 – Vivacitas Oncology, Inc., a privately-heldbiopharmaceutical company focused on tough–to–treat cancers, is proud to present Dr. VolkerW. Stieber, MD, as a welcome addition to its distinguished Neuro-Oncology Advisory Board. Dr. Volker W. Stieber, MD Dr. Stieber is board certified in Radiation Oncology. He is a graduate of the University […]
Vivacitas Oncology Adds Dr. Katherine Peters, MD, PhD, FAAN to its Neuro-Oncology Advisory Board
Walnut Creek, CA, USA, January 31, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, continues to grow its Neuro-Oncology Advisory Board with top clinicians and researchers in the field with the addition of Dr. Katherine Peters, MD, PhD, FAAN, Associate Professor of Neurosurgery at Duke University School of Medicine. About Dr. […]
Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit
Walnut Creek, CA, USA, January 18, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, will be attending and presenting a poster on its lead asset, AR-67 at the 3rd Annual Glioblastoma Drug Development Summit, a virtual event held from January 18th to 20th, 2022. The Glioblastoma Drug Development Summit is the only […]
Dr. Erkut Borazanci, MD, Joins Vivacitas Oncology’s Pancreatic Medical Advisory Board
Walnut Creek, CA, USA, January 17, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Erkut Borazanci, MD, has joined its Pancreatic Medical Advisory Board. “To us, engaging with the best oncology specialists is fundamental to achieving our goal of developing unique treatment alternatives that will potentially change […]
Vivacitas Oncology to present AR-67 at the Biotech Showcase Investor Conference
WALNUT CREEK, CALIFORNIA, US, January 10, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately held clinical stage biopharmaceutical company focused on tough–to–treat cancers, today announced it will present at the 2022 Biotech ShowcaseTM conference with an on-line presentation. Mark Suseck, Vivacitas CEO & Director will present an overview of the company, it’s lead compound […]
Vivacitas Oncology welcomes Dr. Jai Grewal, MD, and expands its Neuro-Oncology Advisory Board
WALNUT CREEK, CALIFORNIA, US, January 3, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately held oncology company focused on tough–to–treat cancers, is pleased to announce that Dr. Jai Grewal, MD, has agreed to become a new member of their distinguished Neuro-Oncology Advisory Board. Dr. Grewal will be joining Dr. Andrew Lassman, MD, MS, FAAN in […]